Photo: alphaspirit / Shutterstock.com
Horizon Pharma is set to acquire Dublin-based Vidara Therapeutics in a merger worth about $660 million, the companies announced on March 19.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Horizon Pharma, Vidara Therapeutics, Actimmune, merger, M&A